Georgii Manikhas

Statistics

Publications

Citations

188

H-Index

Active since

2018

Affiliations

Janssen (United States)(Current)

Georgii Manikhas is an author at Janssen (United States) specializing in hematologic malignancy pharmacotherapy, medicine, and drug interactions in chemotherapy.

ORCID

Publications per year

2018–2018

Publications

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 140 citations

Medicine, Hematology, Oncology +15

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

Jan de Jong, Peter Hellemans, Severijn De Wilde et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2018 · 48 citations

Medicine, Pharmacology, Pharmacotherapy +16

1–2 of 2